SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-300218
Filing Date
2022-12-07
Accepted
2022-12-07 17:06:41
Documents
15
Period of Report
2022-12-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d420073d8k.htm   iXBRL 8-K 29726
2 EX-1.1 d420073dex11.htm EX-1.1 198635
3 EX-5.1 d420073dex51.htm EX-5.1 8491
7 GRAPHIC g420073g1207092349823.jpg GRAPHIC 2409
  Complete submission text file 0001193125-22-300218.txt   423112

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA sndx-20221206.xsd EX-101.SCH 2847
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE sndx-20221206_lab.xml EX-101.LAB 18757
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sndx-20221206_pre.xml EX-101.PRE 11708
9 EXTRACTED XBRL INSTANCE DOCUMENT d420073d8k_htm.xml XML 3497
Mailing Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451 781-419-1400
Syndax Pharmaceuticals Inc (Filer) CIK: 0001395937 (see all company filings)

IRS No.: 320162505 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37708 | Film No.: 221450784
SIC: 2834 Pharmaceutical Preparations